- Home
- CRSP vs RARE Comparison
CRSP vs RARE Comparison
Compare CRSP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- RARE
- Stock Information
- Founded
- CRSP 2013
- RARE 2010
- Country
- CRSP Switzerland
- RARE United States
- Employees
- CRSP N/A
- RARE N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CRSP Health Care
- RARE Health Care
- Exchange
- CRSP Nasdaq
- RARE Nasdaq
- Market Cap
- CRSP 4.2B
- RARE 3.5B
- IPO Year
- CRSP 2016
- RARE 2014
- Fundamental
- Price
- CRSP $59.12
- RARE $41.19
- Analyst Decision
- CRSP Buy
- RARE Strong Buy
- Analyst Count
- CRSP 16
- RARE 15
- Target Price
- CRSP $71.20
- RARE $90.53
- AVG Volume (30 Days)
- CRSP 3.5M
- RARE 1.1M
- Earning Date
- CRSP 08-04-2025
- RARE 07-31-2025
- Dividend Yield
- CRSP N/A
- RARE N/A
- EPS Growth
- CRSP N/A
- RARE N/A
- EPS
- CRSP N/A
- RARE N/A
- Revenue
- CRSP $37,675,000.00
- RARE $590,689,000.00
- Revenue This Year
- CRSP $30.25
- RARE $18.94
- Revenue Next Year
- CRSP $268.62
- RARE $28.93
- P/E Ratio
- CRSP N/A
- RARE N/A
- Revenue Growth
- CRSP N/A
- RARE 33.46
- 52 Week Low
- CRSP $30.04
- RARE $29.59
- 52 Week High
- CRSP $63.68
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- CRSP 83.65
- RARE 67.25
- Support Level
- CRSP $50.26
- RARE $38.91
- Resistance Level
- CRSP $53.08
- RARE $39.98
- Average True Range (ATR)
- CRSP 2.78
- RARE 1.49
- MACD
- CRSP 0.93
- RARE 0.34
- Stochastic Oscillator
- CRSP 98.13
- RARE 95.45
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.